Donald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analysts believe the long-term impact could be limited, citing India's manufacturing cost advantage, US-based production facilities of several drugmakers and uncertainty over how and when the tariffs will be implemented.
Donald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analysts believe the long-term impact could be limited, citing India's manufacturing cost advantage, US-based production facilities of several drugmakers and uncertainty over how and when the tariffs will be implemented.
<iframe src="https://hindustansphere.com/embed/cluster/a105781f6d74b935f2efd29399a244de3e3be597" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investors"></iframe>
